Siponimod for relapsing-remitting multiple sclerosis: a single-center, real-world cohort study in China
Siponimod was associated with reduced relapse activity and stable disability in patients with RRMS and may provide potential cognitive benefit. Given the high incidence of lymphopenia, close monitoring of peripheral lymphocyte counts is warranted.
Authors
- Chao Quan (ORCID: https://orcid.org/0000-0003-3388-5215)
- Hongmei Tan
- Chuanzhen Lu
- Yue Gao
- Qiang Dong
- Lei Zhou
- Jingzi ZhangBao
- Chongbo Zhao
Institutions
- National Clinical Research Center for Digestive Diseases (CN)
- National Institute of Neurological Disorders and Stroke (US)
- Huashan Hospital (CN)
Publication Details
- Journal
- BMC Neurology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1186/s12883-026-04727-6
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00